Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Targeting protein prenylation in progeria.

Tytuł:
Targeting protein prenylation in progeria.
Autorzy:
Young SG; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. />Yang SH
Davies BS
Jung HJ
Fong LG
Źródło:
Science translational medicine [Sci Transl Med] 2013 Feb 06; Vol. 5 (171), pp. 171ps3.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Review
Język:
English
Imprint Name(s):
Original Publication: Washington, DC : American Association for the Advancement of Science
MeSH Terms:
Progeria/*drug therapy
Protein Prenylation/*drug effects
Animals ; Cell Nucleus Shape/drug effects ; Clinical Trials as Topic ; Enzyme Inhibitors/pharmacology ; Enzyme Inhibitors/therapeutic use ; Farnesyltranstransferase/antagonists & inhibitors ; Farnesyltranstransferase/metabolism ; Humans ; Lamins/metabolism ; Progeria/enzymology ; Progeria/genetics ; Progeria/pathology
References:
Annu Rev Biochem. 1996;65:241-69. (PMID: 8811180)
Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3000-4. (PMID: 1557405)
Nature. 2003 May 15;423(6937):293-8. (PMID: 12714972)
Nat Genet. 2002 May;31(1):94-9. (PMID: 11923874)
Biochim Biophys Acta. 2008 Jan-Feb;1781(1-2):36-9. (PMID: 18082640)
Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18111-6. (PMID: 15608054)
Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12879-84. (PMID: 16129833)
Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15902-7. (PMID: 18838683)
J Clin Invest. 2006 Aug;116(8):2115-21. (PMID: 16862216)
J Lipid Res. 2010 Feb;51(2):400-5. (PMID: 19965595)
Muscle Nerve. 2004 Oct;30(4):444-50. (PMID: 15372542)
J Clin Invest. 2006 Mar;116(3):743-52. (PMID: 16511604)
Sci Transl Med. 2011 Oct 26;3(106):106ra107. (PMID: 22030750)
Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13049-54. (PMID: 12235369)
Cell Rep. 2012 Jul 26;2(1):1-9. (PMID: 22840390)
Hum Mol Genet. 2009 Jul 1;18(13):2462-71. (PMID: 19376814)
Sci Transl Med. 2011 Jun 29;3(89):89ra58. (PMID: 21715679)
Science. 2012 Sep 28;337(6102):1594-5. (PMID: 23019622)
Science. 2006 Mar 17;311(5767):1621-3. (PMID: 16484451)
Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12873-8. (PMID: 16129834)
Hum Mol Genet. 2010 Apr 15;19(8):1603-17. (PMID: 20106865)
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):E423-31. (PMID: 22308344)
J Cell Sci. 1994 Jan;107 ( Pt 1):61-7. (PMID: 8175923)
Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10291-6. (PMID: 16014412)
Hum Mutat. 2007 Sep;28(9):882-9. (PMID: 17469202)
J Biol Chem. 2010 Jul 2;285(27):20818-26. (PMID: 20439468)
Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16666-71. (PMID: 23012407)
J Lipid Res. 2012 Jan;53(1):77-86. (PMID: 22039581)
J Biol Chem. 1997 May 30;272(22):14459-64. (PMID: 9162087)
J Clin Invest. 2008 Oct;118(10):3291-300. (PMID: 18769635)
Science. 1993 Jun 25;260(5116):1937-42. (PMID: 8316834)
Nat Med. 2005 Apr;11(4):440-5. (PMID: 15750600)
J Invest Dermatol. 2005 Nov;125(5):913-9. (PMID: 16297189)
J Clin Invest. 2009 Jul;119(7):1825-36. (PMID: 19587457)
J Pediatr. 1972 Apr;80(4):697-724. (PMID: 4552697)
Hum Mol Genet. 2011 Feb 1;20(3):436-44. (PMID: 21088111)
Hum Mol Genet. 2010 Jul 1;19(13):2682-94. (PMID: 20421363)
Nat Med. 2008 Jul;14(7):767-72. (PMID: 18587406)
J Lipid Res. 2005 Dec;46(12):2531-58. (PMID: 16207929)
Grant Information:
R01 HL089781 United States HL NHLBI NIH HHS; R01 HL086683 United States HL NHLBI NIH HHS; R01 AG035626 United States AG NIA NIH HHS; HL086683 United States HL NHLBI NIH HHS; AG035626 United States AG NIA NIH HHS; HL089781 United States HL NHLBI NIH HHS
Substance Nomenclature:
0 (Enzyme Inhibitors)
0 (Lamins)
EC 2.5.1.29 (Farnesyltranstransferase)
Entry Date(s):
Date Created: 20130208 Date Completed: 20140117 Latest Revision: 20211021
Update Code:
20240104
PubMed Central ID:
PMC3725554
DOI:
10.1126/scitranslmed.3005229
PMID:
23390246
Czasopismo naukowe
A clinical trial of a protein farnesyltransferase inhibitor (lonafarnib) for the treatment of Hutchinson-Gilford progeria syndrome (HGPS) was recently completed. Here, we discuss the mutation that causes HGPS, the rationale for inhibiting protein farnesyltransferase, the potential limitations of this therapeutic approach, and new potential strategies for treating the disease.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies